References
- Carlomagno F, Vitagliano D, Guida T, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET onco-genes. Cancer Res. 2002; 62 (4): 1077–82.
- Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62 (24): 7284–90.
- Carlomagno F, Vitagliano D, Guida T, et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino 5 (4 chloro phenyl) 7 (t butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab. 2003; 88 (4): 1897–902.
- Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyro-sine kinase confer resistance to selective kinase inhibitors. Oncogene, 2004; 23 (35): 5958–67.